| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 803303 | 25 ug | $245 | ||
| 803304 | 100 ug | $595 |
| Application | FC |
|---|---|
| Format | Liquid, APC |
| Expression Host | HEK293 |
| Target Name | PD1, PDCD1, CD279, SLEB2 |
| Species | Human |
| Sources | Human PD-1 protein (NP_005009.2) (Leu25-Gln167) with C-terminus Fc tag is expressed in HEK293 cells and conjugated to APC |
| Accession Number | Q15116 |
| Molecular Weight | The protein has a predicted molecular weight of 19 kDa. Under DTT-reducing conditions, it migrates at approximately 25-30 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag | C-Fc |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months. |
Programmed Death-1 receptor (PD-1, also known as CD279) is a type I transmembrane protein and an immunoregulatory receptor of the CD28/CTLA-4 family. It is expressed on activated T cells, B cells, monocytes, dendritic cells, and some thymocytes. PD-1 binds to ligands PD-L1 and PD-L2, transmitting co-inhibitory signals that suppress T-cell activation, proliferation, cytokine production, and cytotoxic activity by dephosphorylating key signaling molecules. This mechanism promotes immune tolerance and prevents autoimmunity but is exploited by tumors to evade immune surveillance, as many tumors upregulate PD-L1. When tumor-expressed PD-L1 engages PD-1 on immune cells, it blocks T-cell activation and promotes immune exhaustion. Monoclonal antibodies targeting the PD-1/PD-L1 pathway have revolutionized cancer therapy by releasing this immune brake, enhancing anti-tumor immunity and leading to tumor regression in many cancers. Examples include nivolumab and pembrolizumab. This immunotherapy approach is now a major focus in oncology, offering a powerful tool to boost the immune system against cancer and reshape treatment paradigms.
APC Conjugated Human PD1 Protein (C-Fc) TDS
Have a product or application question? Consult our FAQs or contact us.
